Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Head & Neck 1Gynecologic 1

Conditions

Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

Paclitaxel 144pembrolizumab 122Carboplatin 110Bevacizumab 92Cisplatin 68Specimen Handling 62olaparib 52Magnetic Resonance Spectroscopy 51Gemcitabine 41Nivolumab 37Biopsy 36liposomal doxorubicin 34Taxes 34Cyclophosphamide 32Blood Specimen Collection 30niraparib 27Doxorubicin 27lenvatinib 26Topotecan 26Letrozole 25Drug Therapy 24Immunoglobulin G 23Brachytherapy 22fludarabine 21atezolizumab 21Radiotherapy 21Disulfides 21durvalumab 19dostarlimab 19Surveys and Questionnaires 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
TP protocol × Gynecologic × 1 year × Clear all
NCT06532539 2026-04-24

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
30 enrolled
Gynecologic

Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡